The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VKTX | -21.57% | +496.66% | +42.94% | +319% |
| S&P | +14.11% | +87.98% | +13.46% | +227% |
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.11M | -31.0% |
| Market Cap | $2.96B | -57.9% |
| Market Cap / Employee | $57.94M | 0.0% |
| Employees | 51 | 0.0% |
| Net Income | -$90.79M | -264.0% |
| EBITDA | -$98.45M | -169.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $100.38M | 99.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.32M | -57.9% |
| Short Term Debt | $0.44M | -9.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.31% | -13.3% |
| Return On Invested Capital | -25.49% | -0.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$94.00M | -328.0% |
| Operating Free Cash Flow | -$94.00M | -328.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.92 | 3.06 | 3.51 | 3.71 | -51.27% |
| Price to Tangible Book Value | 4.92 | 3.06 | 3.51 | 3.71 | -51.27% |
| Enterprise Value to EBITDA | -77.59 | -33.52 | -29.07 | -22.73 | -86.39% |
| Return on Equity | -17.9% | -14.4% | -20.0% | -29.2% | 88.61% |
| Total Debt | $1.12M | $1.00M | $0.88M | $0.76M | -38.87% |
No podcast episodes available.
VKTX earnings call for the period ending June 30, 2022.
VKTX earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
